ADHD: which medications are most effective and safe?

Featured

In his debut blog, Franco De Crescenzo summarises a narrative review that finds good evidence for the short-term pharmacological treatment of ADHD.

[read the full story...]

Prison and mental illness: the unmet needs associated with reincarceration

Featured

Danny Whiting reviews a recent Canadian prison study which finds that schizophrenia, bipolar disorder and homelessness are some of the factors significantly associated with reincarceration.

[read the full story...]

Drug treatment of ADHD in children and young people with ASD #CAMHScampfire

Mental Health Awareness concept for ADHD. letters spelling ADHD.

Douglas Badenoch appraises an up-to-date systematic review and decision pathway for the drug treatment of ADHD symptoms in young people with autism spectrum disorder.

Follow #CAMHScampfire on Twitter at 5pm BST on Tuesday 25th May for an online journal club discussing this paper. Or sign up now to join the free webinar hosted by ACAMH.

[read the full story...]

The global drug problem: who cares? #LxAddictions19

shutterstock_161191178

Ian Hamilton shares his thoughts on the new Drug Use series published yesterday in The Lancet: The global drug problem – change but not progression.

[read the full story...]

Medication for ADHD: what works for adults, adolescents and children

guilian-fremaux-1281811-unsplash

Dean Connolly is impressed by a recent systematic review and network meta-analysis, which compares the efficacy and tolerability of medication for ADHD in children, young people and adults.

[read the full story...]

Novel Psychoactive Substances: bridging the knowledge gap

valor-kopeny-31405

Derek Tracy takes a first look at the Novel Psychoactive Substances in the UK Project; an NIHR-funded empirical and conceptual review that recommends research priorities in the field.

[read the full story...]

Novel Psychoactive Substances: important information for health professionals

Screen Shot 2017-03-02 at 11.02.12

Harry Sumnall, Ian Hamilton and Mark Monaghan provide an overview of Novel Psychoactive Substances (NPS) aimed at health professionals and others who work with people who use these new psychoactive substances.

[read the full story...]

Cardiovascular safety of methylphenidate

6856794287_cbb9e26110_b

Samuele Cortese considers the findings of a recent nationwide self controlled case series study of the cardiovascular safety of methylphenidate use in children and young people with ADHD.

[read the full story...]

Amphetamines and methylphenidate for paediatric ADHD: meta-analysis of n-of-1 trials

1850210315_a332da28ea_b

Samuele Cortese publishes his debut Mental Elf blog on a meta-analysis of n-of-1 trials, which shows that amphetamine derivatives and methylphenidate are superior to placebo, in the short term, for paediatric ADHD.

[read the full story...]

Methylphenidate for ADHD: have Cochrane got it wrong this time?

8369519411_9d2fc25b5e_k

Chris Hollis appraises a recent Cochrane systematic review, which casts doubt over the quality of trial evidence and the clinical effectiveness of Methylphenidate for ADHD.

[read the full story...]